Minneapolis, MN – According to filings with the U.S. Securities and Exchange Commission, Celcuity is raising $155,999,997.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Brian Sullivan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Celcuity
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company’s lead therapeutic candidate is gedatolisib, a potent, reversible dual inhibitor that selectively targets all Class I isoforms of PI3K and mTOR. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. The company expects to initiate a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis.

To learn more about Celcuity, visit http://celcuity.com/

Contact:
Brian Sullivan, Chief Executive Officer
763-392-0767
bsullivan@celcuity.com
https://www.linkedin.com/in/brian-sullivan-6202621/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved